Roy Buchanan
Stock Analyst at JMP Securities
(0)
# 4811
Out of 5,218 analysts
51
Total ratings
27.50%
Success rate
-24.63%
Average return
Main Sectors:
Top Industries:
| Name | Action | Price Target | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
Enanta Pharma | Reiterates: Market Outperform | 22 21 | 6.06 | 246.53% | 11 | Nov 26, 2024 | |
HOOKIPA Pharma | Maintains: Market Outperform | 24 7 | 2.14 | 227.1% | 2 | Nov 21, 2024 | |
AN2 Therapeutics | Reiterates: Market Outperform | 5 5 | 1.44 | 247.22% | 5 | Nov 19, 2024 | |
Gritstone Bio | Downgrades: Market Perform | n/a | n/a | n/a | 5 | Oct 1, 2024 | |
CureVac | Reiterates: Market Outperform | 16 16 | 3.15 | 407.94% | 7 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Market Outperform | 4 5 | 3.48 | 43.68% | 5 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Market Outperform | 12 | 2.29 | 424.02% | 1 | Jan 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Market Outperform | 25 27 | 12.97 | 108.17% | 5 | Nov 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Market Perform | n/a | n/a | n/a | 3 | Jul 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Market Outperform | 15 | 2.23 | 572.65% | 1 | Mar 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Market Outperform | 443 448 | 606.64 | -26.15% | 2 | Mar 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Market Perform | 14 16 | 8.37 | 91.16% | 1 | Mar 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Market Perform | n/a | n/a | n/a | 2 | Feb 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Market Outperform | 420 | 2.61 | 15991.95% | 1 | Sep 14, 2021 |